Tracking vaccine lot lifecycles using reports to the Vaccine Adverse Event Reporting System (VAERS)

Authors

  • Gustavo H. Dayan,

    Corresponding author
    1. Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
    • Centers for Disease Control and Prevention, National Immunization Program 1600 Clifton Road, Mailstop E-61, Atlanta, GA 30333.
    Search for more papers by this author
  • John Iskander,

    1. Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • John Glasser,

    1. Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • Roseanne English-Bullard,

    1. Office of Information Science and Technology, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • Kathleen E. Fullerton,

    1. Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • Robert Chen

    1. Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author

  • No conflict of interest was declared

Abstract

Purpose

There is currently no systematically available information available on how rapidly a specific lot of vaccine is used once distributed. We used data from reports to the Vaccine Adverse Event Reporting System (VAERS) to develop a proxy means of surveillance for the lifecycle of selected vaccine lots.

Methods

A convenience sample, consisting of selected lots of: diphtheria, tetanus, and acellular pertussis (DTaP), Haemophilus influenzae type b (Hib), Hepatitis B, and varicella vaccines, was selected for lifecycle analysis. Assuming that circulation of a vaccine lot is proportional to vaccine-specific adverse event (AE) reporting for that vaccine type, we constructed Gamma distributed usage models and compared them with lot-specific VAERS reports to estimate the actual lifecycle of lots in the system.

Results

Evidence of lot circulation was detected within 1–2 months, and a peak was observed 3–4 months after the vaccine release date for most of the study vaccines. Ninety percent of the vaccine doses in each lot were estimated to be used within 5–9 months of distribution. The length of time a vaccine lot was in use ranged from 5 to 17 months from earliest vaccination date.

Conclusions

Our modeled and inferred administration of the selected lots of different vaccines were concordant. This method may be useful for spatial and temporal tracking of vaccine lot utilization. Copyright © 2005 John Wiley & Sons, Ltd.

Ancillary